MX2022009476A - Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. - Google Patents
Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.Info
- Publication number
- MX2022009476A MX2022009476A MX2022009476A MX2022009476A MX2022009476A MX 2022009476 A MX2022009476 A MX 2022009476A MX 2022009476 A MX2022009476 A MX 2022009476A MX 2022009476 A MX2022009476 A MX 2022009476A MX 2022009476 A MX2022009476 A MX 2022009476A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- binding fragments
- antl
- antibodies
- tmprss2 antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062972338P | 2020-02-10 | 2020-02-10 | |
| US202063021016P | 2020-05-06 | 2020-05-06 | |
| US202063094199P | 2020-10-20 | 2020-10-20 | |
| PCT/US2021/017290 WO2021163076A1 (en) | 2020-02-10 | 2021-02-09 | ANTl-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009476A true MX2022009476A (es) | 2022-08-22 |
Family
ID=74798119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009476A MX2022009476A (es) | 2020-02-10 | 2021-02-09 | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11999799B2 (https=) |
| EP (1) | EP4103619A1 (https=) |
| JP (2) | JP7772702B2 (https=) |
| KR (1) | KR20220140503A (https=) |
| CN (1) | CN115427457A (https=) |
| AU (1) | AU2021219671A1 (https=) |
| CA (1) | CA3163164A1 (https=) |
| IL (1) | IL294529A (https=) |
| MX (1) | MX2022009476A (https=) |
| WO (1) | WO2021163076A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11806507B2 (en) | 2020-12-22 | 2023-11-07 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering an antibody treatment via infusion |
| CA3202742A1 (en) * | 2020-12-22 | 2022-06-30 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via rapid infusion |
| US12133966B2 (en) | 2020-12-22 | 2024-11-05 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering an antibody treatment via infusion |
| US20250019425A1 (en) * | 2021-11-12 | 2025-01-16 | Adrx, Inc. | Transthyretin (ttr) monomer binding antibodies |
| US20250277059A1 (en) * | 2022-04-12 | 2025-09-04 | Riken | Antibody used to treat coronavirus infection |
| CN116003611B (zh) * | 2022-08-17 | 2024-02-27 | 中南大学湘雅医院 | 抗tmprss2抗体及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| DK1299727T3 (da) | 2000-07-12 | 2009-06-15 | Agensys Inc | Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US8354508B2 (en) | 2006-07-21 | 2013-01-15 | Diadexus, Inc. | PRO115 antibody compositions and methods of use |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| EP2285833B1 (en) | 2008-05-16 | 2014-12-17 | Ablynx N.V. | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| BR112014025339A8 (pt) | 2012-04-16 | 2018-01-16 | Regeneron Pharma | método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo. |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| DK3422845T3 (da) | 2016-02-29 | 2021-08-30 | Regeneron Pharma | Gnavere med et humaniseret tmprss-gen |
| CN111936517B (zh) | 2018-01-26 | 2025-04-18 | 瑞泽恩制药公司 | 抗tmprss2抗体和抗原结合片段 |
-
2021
- 2021-02-09 MX MX2022009476A patent/MX2022009476A/es unknown
- 2021-02-09 JP JP2022547208A patent/JP7772702B2/ja active Active
- 2021-02-09 CA CA3163164A patent/CA3163164A1/en active Pending
- 2021-02-09 WO PCT/US2021/017290 patent/WO2021163076A1/en not_active Ceased
- 2021-02-09 US US17/171,941 patent/US11999799B2/en active Active
- 2021-02-09 CN CN202180013863.0A patent/CN115427457A/zh active Pending
- 2021-02-09 EP EP21708898.8A patent/EP4103619A1/en active Pending
- 2021-02-09 AU AU2021219671A patent/AU2021219671A1/en active Pending
- 2021-02-09 IL IL294529A patent/IL294529A/en unknown
- 2021-02-09 KR KR1020227026885A patent/KR20220140503A/ko active Pending
-
2024
- 2024-04-22 US US18/642,721 patent/US20240343831A1/en active Pending
-
2025
- 2025-11-06 JP JP2025187155A patent/JP2026027362A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4103619A1 (en) | 2022-12-21 |
| JP2023513124A (ja) | 2023-03-30 |
| CA3163164A1 (en) | 2021-08-19 |
| JP2026027362A (ja) | 2026-02-18 |
| CN115427457A (zh) | 2022-12-02 |
| AU2021219671A1 (en) | 2022-07-14 |
| JP7772702B2 (ja) | 2025-11-18 |
| WO2021163076A1 (en) | 2021-08-19 |
| IL294529A (en) | 2022-09-01 |
| US20240343831A1 (en) | 2024-10-17 |
| US20210246226A1 (en) | 2021-08-12 |
| KR20220140503A (ko) | 2022-10-18 |
| US11999799B2 (en) | 2024-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006462A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| MX2022009476A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| PH12021550793A1 (en) | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments | |
| MX2022014598A (es) | Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno. | |
| PH12022550033A1 (en) | Compounds useful to treat influenza virus infections | |
| WO2018237148A8 (en) | Multispecific antibodies that target hiv gp120 and cd3 | |
| PH12018502673A1 (en) | Anti-zika virus antibodies and methods of use | |
| EA202191622A1 (ru) | Стабилизированные растворимые f-белки rsv до слияния | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| EA202191736A1 (ru) | Комбинированная терапия hbv | |
| EA202090559A1 (ru) | Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение | |
| PH12021552903A1 (en) | Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof | |
| CR20220660A (es) | Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2 | |
| EA202192923A1 (ru) | Антитела и способы лечения инфекции, вызываемой вирусом гриппа а | |
| CL2024000091A1 (es) | Anticuerpos y fragmentos de unión al antígeno antiglicoproteína de la espícula de sars-cov-2 | |
| PH12020551051A1 (en) | Human antibodies to influenza hemagglutinin | |
| PH12023551390A1 (en) | Broadly neutralizing antibodies against influenza neuraminidase | |
| WO2019053613A3 (en) | Combination treatment for cancer | |
| MX2023005653A (es) | Anticuerpos contra los virus de la influenza a. | |
| MX2009005026A (es) | Anticuerpos anti-tsg101 y sus usos para tratamiento de infecciones virales. | |
| MX2021014882A (es) | Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa. | |
| WO2020191181A9 (en) | Monoclonal antibodies for prevention and treatment of herpes simplex viral infections | |
| WO2019209974A3 (en) | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination | |
| WO2020053742A3 (en) | Anti-hla-hbv peptide antibodies | |
| PH12021550987A1 (en) | Anti-rabies monoclonal antibodies and cocktail thereof |